Isospaglumic Acid

Isospaglumic Acid

SCHEMBL288515

CC(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)O

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GNPAT O15228 1/20 0.70
FOLH1 Q04609 8/20 0.56
NAALAD2 Q9Y3Q0 2/20 0.56
RIMKLA Q8IXN7 1/20 0.56
BMP1 P13497 2/20 0.48
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
ALOX15 P16050 1/20 0.47
NFKB1 P19838 1/20 0.47
PTGS2 P35354 1/20 0.47
THPO P40225 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 1/20 0.46
GGH Q92820 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isospaglumic Acid SCHEMBL27542882 1.00 GNPAT (0.70) GNPATFOLH1NAALAD2RIMKLABMP1
Isospaglumic Acid SCHEMBL288514 1.00 GNPAT (0.70) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL31194414 1.00 GNPAT (0.70) GNPATFOLH1NAALAD2RIMKLABMP1
Isospaglumic Acid SCHEMBL31121839 1.00 GNPAT (0.70) GNPATFOLH1NAALAD2RIMKLABMP1
Isospaglumic Acid SCHEMBL6438535 0.98 GNPAT (0.68) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL29517621 0.94 GNPAT (0.63) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL13467302 0.93 GNPAT (0.60) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL17950968 0.93 GNPAT (0.60) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL19106177 0.93 GNPAT (0.60) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL2248714 0.93 GNPAT (0.60) GNPATFOLH1NAALAD2RIMKLABMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114965800-B Renal clear cell carcinoma biomarker and application thereof in early screening 山西医科大学 2024-02-20 CN claimed
US-20240033124-A1 DRUG DELIVERY CONTACT LENS AND OPHTHALMIC PHARMACEUTICAL COMPOSITION DAE WON PHARMACEUTICAL CO., LTD (KR) 2024-02-01 US claimed
EP-4275675-A1 DRUG DELIVERY CONTACT LENS AND OPHTHALMIC PHARMACEUTICAL COMPOSITION Dae Won Pharmaceutical Co., Ltd. (KR) 2023-11-15 EP claimed
CN-113960200-B Use of metabolic markers for diagnosing ADHD combined tic disorders in children 首都医科大学附属北京儿童医院 2023-06-20 CN claimed
CN-114965800-A Renal clear cell carcinoma biomarker and application thereof in early screening 山西医科大学 2022-08-30 CN claimed
US-20210388080-A1 TARGETING CONSTRUCTS BASED ON NATURAL ANTIBODIES AND USES THEREOF DEPARTMENT OF VETERANS AFFAIRS (US) 2021-12-16 US claimed
EP-3546940-B1 BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME METABOLON INC (US) 2021-02-17 EP claimed
EP-3546940-A1 BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME Metabolon, Inc. (US) 2019-10-02 EP claimed
EP-2564194-B1 METABOLIC BIOMARKERS OF AUTISM WISCONSIN ALUMNI RES FOUND (US) 2019-07-10 EP claimed
US-10330688-B2 Metabolic biomarkers of autism WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2019-06-25 US claimed
US-20120190055-A1 MOLECULE BIOMARKERS OF AUTISM STEMINA BIOMARKER DISCOVERY, INC. (US) 2012-07-26 US claimed
WO-2011139914-A1 METABOLIC BIOMARKERS OF AUTISM WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-11-10 WO claimed
WO-2011044253-A1 METABOLIC BIOMARKERS OF DRUG-INDUCED CARDIOTOXICITY WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-04-14 WO claimed
US-20110081675-A1 Metabolic Biomarkers Of Drug-Induced Cardiotoxicity WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-04-07 US claimed
US-20100116691-A1 BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF UNIVERSITY OF CONNECTICUT (US) 2010-05-13 US claimed
US-20100104645-A1 METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES BIND BIOSCIENCES, INC. (US) 2010-04-29 US claimed
US-20100087337-A1 High Throughput Fabrication of Nanoparticles BIND BIOSCIENCES, INC. (US) 2010-04-08 US claimed
WO-2010030763-A2 HIGH THROUGHPUT FABRICATION OF NANOPARTICLES BIND BIOSCIENCES, INC. (US) 2010-03-18 WO claimed
US-7399461-B2 Prostate-specific membrane antigen and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2008-07-15 US claimed
EP-1754788-A2 Prostate-specific membrane antigen and uses thereof Sloan-Kettering Institute For Cancer Research (US) 2007-02-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100104645-A1 METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES GNE, EPHA2, PAM GNPAT 1063/4885FOLH1 1373/4885NAALAD2 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.